Targeted therapies: One step closer to drugging p53.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Suppression of mitochondrial energy production by a photosynthetic bacterial cupredoxin peptide inhibits tumor growth.Signal transduction and targeted therapy · 2026
   Article
2. Improvement of DCIS resection using intraoperative imaging with ICG-p28.Scientific reports · 2025
   Article
3. Intracellular redistribution of cell-penetrating peptide p28: A mechanism for enhanced anti-cancer activity.Journal of controlled release : official journal of the Controlled Release Society · 2025
   Article
4. Applications of cell penetrating peptide-based drug delivery system in immunotherapy.Frontiers in immunology · 2025
   Review
5. Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.International journal of molecular sciences · 2023
   Review
6. Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression.Communications biology · 2023
   Article
7. Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer.Cancers · 2022
   Review
8. Image-guided surgery with a new tumour-targeting probe improves the identification of positive margins.EBioMedicine · 2022
   Article
9. Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy.Frontiers in oncology · 2022
   Article
10. A Method of Tumor In Vivo Imaging with a New Peptide-Based Fluorescent Probe.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
11. Improved Classification of Lung Cancer Using Radial Basis Function Neural Network with Affine Transforms of Voss Representation.PloS one · 2015
    Article

Corrections and comments

• Comment on
  A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.